Furthermore, we investigate the expression of additional potential miR-17 targets, namely, p21 [21] and TGFBR2 [32], that are involved in TGFβ signaling, known to be impaired in MS patients. This evidence concerns the gene TGFBR2 and myeloid sarcoma.